CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products.

[2] The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.

[5][6][7] In 1904, Von Behring founded the Behringwerke in Marburg, Germany, for experimental work on disease prevention and the manufacturing of sera and vaccines.

In 1954, Australian CSL officer Val Bazeley assisted Jonas Salk in producing the experimental polio vaccine used in the first clinical trials in the US.

That same year, the National Organization for Rare Disorders (NORD) recognised CSL Behring for developing and marketing a treatment in the U.S. for acute bleeding episodes in patients with congenital fibrinogen deficiency, and the Swiss government awarded CSL Behring the Tell Award.

Major manufacturing centers are located in Bern, Switzerland;Marburg, Germany; Kankakee, Illinois; and Broadmeadows, Australia.